PFM Health Sciences, LP holds a diversified book of 77 stocks worth $950.2M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Indivior Pharmaceuticals Inc and trimmed Eli Lilly & Co. Their largest long position is Tenet Healthcare Corp at 8% of the equity book. They also disclosed $87.6M in put options (a bearish bet) and $58.9M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1442756/holdings"
Use Arkolith to show PFM Health Sciences, LP's latest holdings, largest changes, and filing provenance.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
91% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Tenet Healthcare Corp COM NEW | $75.2M | 398.6K | 7.9% | ▲+0.2% Added · +800 sh | |
| 2 | Eli Lilly & Co COM | $60.5M | 65.8K | 6.4% | ▼−3.7% Reduced · −3K sh | |
| 3 | Penumbra Inc COM | $45.9M | 139.8K | 4.8% | ▼−3.7% Reduced · −5K sh | |
| 4 | Axsome Therapeutics Inc. COM | $44.7M | 264.3K | 4.7% | ▲+5.1% Added · +13K sh | |
| 5 | Ascendis Pharma A/s SPONSORED ADR | $34.8M | 152.0K | 3.7% | ▼−14% Reduced · −26K sh | |
| 6 | Jazz Pharmaceuticals PLC SHS USD | $33.7M | 178.1K | 3.5% | ▲+253% Added · +128K sh | |
| 7 | Neurocrine Biosciences Inc COM | $28.4M | 215.7K | 3.0% | ▲+32% Added · +52K sh | |
| 8 | United Therapeutics Corp Del COM | $23.6M | 39.8K | 2.5% | ▼−41% Reduced · −28K sh | |
| 9 | Glaukos Corp COM | $23.2M | 215.7K | 2.4% | ▲+6.9% Added · +14K sh | |
| 10 | Centessa Pharmaceuticals PLC SPONSORED ADS | $21.0M | 528.2K | 2.2% | ▼−11% Reduced · −63K sh | |
| 11 | Inhibrx Biosciences Inc COM | $20.5M | 305.4K | 2.2% | ▲+15% Added · +40K sh | |
| 12 | Edwards Lifesciences Corp COM | $20.4M | 254.5K | 2.1% | ▲+3.1% Added · +8K sh | |
| 13 | Bridgebio Pharma Inc COM | $19.1M | 257.7K | 2.0% | ▼−16% Reduced · −49K sh | |
| 14 | Madrigal Pharmaceuticals Inc COM | $17.9M | 34.1K | 1.9% | ▲+370% Added · +27K sh | |
| 15 | Indivior Pharmaceuticals Inc COM | $17.5M | 574.7K | 1.8% | ▲New New position | |
| 16 | Ascendis Pharma A/s NOTE 2.250% 4/0 | $16.9M | 11.51M | 1.8% | ▲+8.0% Added · +850K sh | |
| 17 | Unitedhealth Group Inc COM | $15.7M | 58.0K | 1.7% | ▲+15% Added · +7K sh | |
| 18 | Dianthus Therapeutics Inc COM | $14.4M | 172.1K | 1.5% | ▲+73% Added · +73K sh | |
| 19 | Abbott Laboratories COM | $14.4M | 140.4K | 1.5% | ▲New New position | |
| 20 | Revolution Medicines Inc COM | $13.7M | 140.8K | 1.4% | ▼−7.0% Reduced · −11K sh | |
| 21 | Acadia Healthcare Company In COM | $13.6M | 582.7K | 1.4% | ▲New New position | |
| 22 | Neogenomics Inc COM NEW | $13.2M | 1.78M | 1.4% | ▲+5.3% Added · +91K sh | |
| 23 | Cooper Cos Inc COM | $12.1M | 169.8K | 1.3% | ▲+68% Added · +69K sh | |
| 24 | Natera Inc COM | $12.0M | 60.0K | 1.3% | ▲New New position | |
| 25 | Integer Hldgs Corp COM | $11.9M | 135.1K | 1.3% | ▲+27% Added · +28K sh | |
| 26 | Rhythm Pharmaceuticals Inc COM | $11.9M | 136.6K | 1.3% | ▲+240% Added · +96K sh | |
| 27 | Waters Corp COM | $11.8M | 39.8K | 1.2% | ▼−8.0% Reduced · −3K sh | |
| 28 | Amneal Pharmaceuticals Inc COM STK CL A | $11.6M | 930.1K | 1.2% | ▼−37% Reduced · −535K sh | |
| 29 | Praxis Precision Medicines I COM NEW | $11.4M | 35.4K | 1.2% | ▲+14% Added · +4K sh | |
| 30 | Schein Henry Inc COM | $11.3M | 153.1K | 1.2% | ▲New New position | |
| 31 | CG Oncology Inc COM | $11.2M | 165.9K | 1.2% | ▲+1.2% Added · +2K sh | |
| 32 | Merit Med Sys Inc COM | $11.2M | 162.5K | 1.2% | ▲New New position | |
| 33 | Celldex Therapeutics Inc New COM NEW | $10.3M | 325.0K | 1.1% | ▲+144% Added · +192K sh | |
| 34 | Belite Bio Inc SPONSORED ADS | $9.5M | 59.4K | 1.0% | ▲+200% Added · +40K sh | |
| 35 | Dexcom Inc COM | $9.4M | 149.7K | 1.0% | ▼−34% Reduced · −78K sh | |
| 36 | Terns Pharmaceuticals Inc COM | $9.1M | 173.0K | 1.0% | ▲New New position | |
| 37 | Centene Corp Del COM | $8.6M | 263.5K | 0.9% | ▼−64% Reduced · −462K sh | |
| 38 | Viking Therapeutics Inc COM | $8.6M | 263.1K | 0.9% | ▲+39% Added · +74K sh | |
| 39 | Oruka Therapeutics Inc COM | $8.5M | 174.1K | 0.9% | ▲New New position | |
| 40 | Tango Therapeutics Inc COM | $8.5M | 406.2K | 0.9% | ▲New New position | |
| 41 | Soleno Therapeutics Inc COM | $8.3M | 248.2K | 0.9% | ▲+0.1% Added · +287 sh | |
| 42 | Brightspring Health Svcs Inc COM | $8.0M | 187.3K | 0.8% | ▲+58% Added · +69K sh | |
| 43 | Compass Pathways PLC SPONSORED ADS | $7.6M | 1.37M | 0.8% | ▲+75% Added · +587K sh | |
| 44 | Thermo Fisher Scientific Inc COM | $7.3M | 14.8K | 0.8% | ▼−61% Reduced · −23K sh | |
| 45 | Novo-Nordisk A S ADR | $7.2M | 197.2K | 0.8% | ▲New New position | |
| 46 | Stryker Corporation COM | $7.2M | 22.0K | 0.8% | ▼−57% Reduced · −29K sh | |
| 47 | Vera Therapeutics Inc CL A | $7.0M | 174.9K | 0.7% | ▲+62% Added · +67K sh | |
| 48 | Billiontoone Inc CL A | $7.0M | 88.1K | 0.7% | ▲+0.6% Added · +522 sh | |
| 49 | Cardinal Health Inc COM | $6.7M | 31.9K | 0.7% | ▼−49% Reduced · −30K sh | |
| 50 | Icon PLC SHS | $6.4M | 57.5K | 0.7% | ▼−50% Reduced · −58K sh |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | SS SPDR S&P BIOTECH ETFXBI | $58.2M | 455K |
| CALL · bullish | SS HEALTH CARE SELECT SECTORXLV | $35.0M | 239K |
| PUT · bearish | UNITED THERAPEUTICS CORPUTHR | $27.2M | 46K |
| CALL · bullish | UNITED THERAPEUTICS CORPUTHR | $18.8M | 32K |
| CALL · bullish | ASCENDIS PHARMA A/SASNDUSD | $5.1M | 22K |
| PUT · bearish | HCA HEALTHCARE INCHCA | $2.2M | 5K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.